Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 8/20 | 0.50 |
| ▸ | CTSB | P07858 | 6/20 | 0.50 |
| ▸ | CTSK | P43235 | 5/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.48 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 9/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17994244 | 0.93 | PSMB5 (0.47) | CTSSCTSBCTSKL3MBTL1PSMB5 | |
| SCHEMBL16375208 | 0.88 | HSPA5 (0.51) | CTSSCTSBCTSKL3MBTL1MMEL1 | |
| SCHEMBL16375200 | 0.87 | MME (0.53) | CTSSCTSBCTSKL3MBTL1PSMB5 | |
| SCHEMBL16375212 | 0.83 | PTPN1 (0.57) | — | |
| SCHEMBL16375232 | 0.82 | L3MBTL1 (0.59) | CTSSCTSBCTSKL3MBTL1MMEL1 | |
| SCHEMBL16305675 | 0.81 | PPARG (0.47) | L3MBTL1KLKB1 | |
| SCHEMBL17994242 | 0.81 | HSPA5 (0.48) | CTSSCTSBCTSL | |
| SCHEMBL17994239 | 0.80 | MME (0.49) | CTSSCTSBCTSKL3MBTL1PSMB5 | |
| SCHEMBL16375202 | 0.79 | L3MBTL1 (0.58) | CTSSCTSBCTSKL3MBTL1CTSL | |
| SCHEMBL16305952 | 0.78 | L3MBTL1 (0.48) | CTSSCTSBCTSKL3MBTL1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-11-02 | — | — | US | disclosed |
| US-9598430-B2 | GLP-1 receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2017-03-21 | — | — | US | disclosed |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2016-07-28 | — | — | US | disclosed |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | CTSS 3233/4885CTSB 1692/4885CTSK 3229/4885 |
| US-20160214993-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | CTSS 3233/4885CTSB 1692/4885CTSK 3229/4885 |
| US-20150011527-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | CTSS 3233/4885CTSB 1692/4885CTSK 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.